SHARON FAITH LEVY
Medical Practice in Philadelphia, PA

License number
Pennsylvania MD026409E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Philadelphia, PA 19119
LicenseFiles verified this license of Apr 24, 2017 at the Pennsylvania Licensing System.

Personal information

See more information about SHARON FAITH LEVY at radaris.com
Name
Address
Phone
Sharon Levy
4373 Hilltop Cir, Bethlehem, PA 18020
Sharon Levy, age 70
535 Cedarbrook Rd, Southampton, PA 18966
(215) 355-7410
Sharon Levy, age 74
526 Lobinger Ave, Braddock, PA 15104
Sharon Levy, age 70
404 E Mount Airy Ave, Philadelphia, PA 19119
(215) 805-0686
Sharon Levy
6705 Lincoln Dr, Philadelphia, PA 19119

Professional information

Sharon Levy Photo 1

Chief Medical Officer At Prosoft Clinical
Position:
Chief Medical Officer at Prosoft Clinical
Location:
Greater Philadelphia Area
Industry:
Pharmaceuticals
Work:
Prosoft Clinical - 996 Old Eagle School Rd, Suite 1106, Wayne, PA 19087 since Jun 2011 - Chief Medical Officer Graceway Pharmaceuticals Feb 2007 - Apr 2011 - Sr Vice President Clinical Product Development Johnson & Johnson Feb 2005 - Feb 2007 - Sr Director Clinical Development and Medical Affairs Dermik Laboratories (a Division of Rhone Poulenc Rorer) 1997 - 2005 - Sr Director Clinical Research sanofi-aventis May 1992 - Feb 2005 - Sr Director Clinical Development and Medical Affairs
Education:
University of Massachusetts Medical School 1976 - 1980
MD, Medicine Harvard University 1972 - 1976
AB, Biology

Sharon Levy Photo 2

Up To Six Weeks Dosing Regimen For Treating Actinic Keratosis With Pharmaceutical Compositions Formulated With 3.75% Imiquimod

US Patent:
2011026, Oct 27, 2011
Filed:
Jul 18, 2011
Appl. No.:
13/184579
Inventors:
Michael T. Nordsiek - Wayne PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
Assignee:
Graceway Pharmaceuticals, LLC. - Bristol TN
International Classification:
A61K 31/4745, A61P 17/00, A61P 35/00
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

Sharon Levy Photo 3

Combination Therapy With Cryosurgery And Low Dosage Strength Imiquimod To Treat Actinic Keratosis

US Patent:
2011031, Dec 29, 2011
Filed:
Jun 24, 2011
Appl. No.:
13/168796
Inventors:
Michael T. Nordsiek - Wayne PA, US
Sharon F. Levy - Philadelphia PA, US
James Hurn-Joung Lee - St. Paul MN, US
James H. Kulp - West Chester PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Robert Babilon - Boyertown PA, US
Kodumudi S. Balaji - Lansdale PA, US
Valyn S. Bahm - Phoenixville PA, US
International Classification:
A61M 37/00
US Classification:
604 22
Abstract:
The present invention is directed to the use of complementary or combination lesion-directed therapy, such as cryosurgery, and field-directed therapy, such as low dose imiquimod topical therapy with short durations, in combination to treat actinic keratosis (“AK”). In carrying out the present invention, the lesion-directed and field-directed therapies may be applied sequentially or concomitantly, in accordance with the present invention. The novel complementary or combination AK therapy contemplated by the present invention: (1) significantly improves clearance of cryosurgery-treated Aks; (2) treats subclinical AK lesions; (3) treats those visible AK lesions in excess of that cryosurgery can actually treat in a single treatment due to, e.g., patient tolerance, provider treatment limits and/or cryosurgery cost to the patient; and (4) enhances sustained clearance overall, as compared to mono AK lesion-directed therapy.

Sharon Levy Photo 4

Lower Dosage Strength Imiquimod Formulations And Shorter Dosing Regimens For Treating Actinic Keratoses

US Patent:
2011002, Jan 27, 2011
Filed:
Dec 11, 2009
Appl. No.:
12/636613
Inventors:
Michael T. Nordsiek - Berwyn PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Downingtown PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn J. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
Assignee:
Graceway Pharmaceuticals, LLC - Bristol TN
International Classification:
A61K 31/4745, A61P 17/12
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

Sharon Levy Photo 5

Lower Dosage Strength Imiquimod Formulations And Short Dosing Regimens For Treating Genital And Perianal Warts

US Patent:
2012028, Nov 15, 2012
Filed:
Jul 26, 2012
Appl. No.:
13/559473
Inventors:
Michael T. NORDSIEK - Wayne PA, US
Sharon F. LEVY - Philadelphia PA, US
James H. LEE - Devon PA, US
James H. KULP - West Chester PA, US
Kodumudi S. BALAJI - Lansdale PA, US
Tze-Chiang MENG - Lino Lakes MN, US
Jason J. WU - Wayne PA, US
Valyn S. BAHM - Phoenixville PA, US
Robert BABILON - Boyertown PA, US
Assignee:
MEDICIS PHARMACEUTICAL CORPORATION - Scottsdale AZ
International Classification:
A61K 31/4745, A61P 17/12, A61P 15/00
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

Sharon Levy Photo 6

Lower Dosage Strength Imiquimod Formulations And Short Dosing Regimens For Treating Genital And Perianal Warts

US Patent:
2011020, Aug 25, 2011
Filed:
Apr 30, 2010
Appl. No.:
12/771076
Inventors:
Michael T. Nordsiek - Berwyn PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Downingtown PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
Assignee:
Graceway Pharmaceuticals, LLC. - Bristol TN
International Classification:
A61K 31/4745, A61P 17/12
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

Sharon Levy Photo 7

Lower Dosage Strength Imiquimod Formulations And Short Dosing Regimens For Treating Genital And Perianal Warts

US Patent:
2012032, Dec 27, 2012
Filed:
Jun 26, 2012
Appl. No.:
13/533913
Inventors:
Michael T. Nordsiek - Berwyn PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Downingtown PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
Assignee:
Medicis Pharmaceutical Corporation - Scottsdae AZ
International Classification:
A61K 31/4745, A61P 17/12
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

Sharon Levy Photo 8

2 X 2 X 2 Week Treatment Regimen For Treating Actinic Keratosis With Pharmaceutical Compositions Formulated With 2.5% Imiquimod

US Patent:
2011025, Oct 20, 2011
Filed:
Jul 8, 2011
Appl. No.:
13/179315
Inventors:
Michael T. Nordsiek - Wayne PA, US
Sharon F. Levy - Philadelphia PA, US
James H. Lee - Devon PA, US
James H. Kulp - West Chester PA, US
Kodumudi S. Balaji - Lansdale PA, US
Tze-Chiang Meng - Lino Lakes MN, US
Jason J. Wu - Wayne PA, US
Valyn S. Bahm - Phoenixville PA, US
Robert Babilon - Boyertown PA, US
International Classification:
A61K 31/437, A61P 17/12
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

Sharon Levy Photo 9

Lower Dosage Strength Imiquimod Formulations And Short Dosing Regimens For Treating Genital And Perianal Warts

US Patent:
2012032, Dec 27, 2012
Filed:
Jul 26, 2012
Appl. No.:
13/559444
Inventors:
Michael T. NORDSIEK - Wayne PA, US
Sharon F. LEVY - Philadelphia PA, US
James H. LEE - Devon PA, US
James H. KULP - West Chester PA, US
Kodumudi S. BALAJI - Lansdale PA, US
Tze-Chiang MENG - Lino Lakes MN, US
Jason J. WU - Wayne PA, US
Valyn S. BAHM - Phoenixville PA, US
Robert BABILON - Boyertown PA, US
Assignee:
MEDICIS PHARMACEUTICAL CORPORATION - Scottsdale AZ
International Classification:
A61K 31/437, A61P 17/12
US Classification:
514293
Abstract:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

Sharon Levy Photo 10

Method Of Treatment For Dermatological Disorders And Compositions Therefor

US Patent:
2002000, Jan 24, 2002
Filed:
Dec 20, 2000
Appl. No.:
09/741585
Inventors:
Raymond Tobey - Radnor PA, US
Sharon Levy - Philadelphia PA, US
International Classification:
A61K009/16, A61K009/50
US Classification:
424/497000
Abstract:
A composition and method of treatment of dermatological disorders using 5-fluorouracil at levels below about 1.0%. The disorders to be treated include actinic keratosis, non-malignant lesions of the skin and psoriasis.

Medical Practice licenses in Pennsylvania










Other Doctors licenses in Pennsylvania